For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.


Amgen - Recent Press Releases
RSS Feeds RSS
DateTitle 
09/17/14Amgen Foundation Commits €2 Million to Support Science Teachers Across EuropePrinter Friendly Version
09/15/14Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With OsteoporosisPrinter Friendly Version
09/15/14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral DensityPrinter Friendly Version
09/14/14Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart FailurePrinter Friendly Version
09/10/14Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual MeetingPrinter Friendly Version
09/05/14Amgen To Present At The Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
09/02/14Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines AgencyPrinter Friendly Version
09/02/14Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines AgencyPrinter Friendly Version
08/28/14Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High CholesterolPrinter Friendly Version
08/28/14Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDAPrinter Friendly Version